Please Wait
Applying Filters...
menu
    • menu
    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Daxibotulinumtoxin A

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions
    DAXXIFY® Becomes First Facial Injectable to be Named to TIME’s Best Inventions

    26 Oct 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231026772907/en

    BUSINESSWIRE
    26 Oct 2023
    Share Share
    Revance's Botox rival gets FDA approval for painful neck muscle condition
    Revance's Botox rival gets FDA approval for painful neck muscle condition

    15 Aug 2023

    // REUTERS

    https://www.reuters.com/business/healthcare-pharmaceuticals/revances-botox-rival-gets-fda-approval-painful-neck-muscle-condition-2023-08-14/

    REUTERS
    15 Aug 2023
    Share Share
    Revance's Biologic DAXXIFY (daxibotulinumtoxinA) Receives Approval in the U.S.
    Revance's Biologic DAXXIFY (daxibotulinumtoxinA) Receives Approval in the U.S.

    11 Aug 2023

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761127

    FDA
    11 Aug 2023
    Share Share
    Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia
    Revance to Present Data on DAXXIFY for Injection for the Treatment of Cervical Dystonia

    23 Feb 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230223005449/en

    BUSINESSWIRE
    23 Feb 2023
    Share Share
    Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting
    Revance to Present Data on the Efficacy & Safety of DAXXIFY for ASDS Meeting

    10 Oct 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221010005193/en

    BUSINESSWIRE
    10 Oct 2022
    Share Share
    Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY
    Revance Announces Publications Highlighting the Efficacy Profile of DAXXIFY

    19 Sep 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220919005178/en

    BUSINESSWIRE
    19 Sep 2022
    Share Share